Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-M17D1 in HER2 positive/low expression gastrointestinal and solid tumors
NCT06500052Phase 1Recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Jul 2024
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BL-M17D1 in esophageal cancer, gastric cancer (GC), pancreatic cancer (PC) and 2 more, sponsored by Biokin Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 21 days, Maximum Tolerated Dose at 21 days and 1 more. Started Jul 2024; status: recruiting.
02
Drugs
BL-M17D1
03
Conditions
esophageal cancergastric cancer (GC)pancreatic cancer (PC)colorectal cancer (CRC)solid tumor
Beyond the preview
Go deeper on NCT06500052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06500052.